VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share

Related Keywords

Canada , Vancouver , British Columbia , Netherlands , United Kingdom , Canadian , British , Christopherj Moreau , , Company Or Algernon , Algernon Pharmaceuticals , Algernon Pharmaceuticals Inc , Centre For Human Drug Research , Company Phase , Algernon Neuroscience , Stroke Study , Human Drug Research , Idmt , Stroke , Clinical Trial Design , Research Program , Algernon ,